169 related articles for article (PubMed ID: 24491571)
1. Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice.
Wang L; Tang Y; Eisner W; Sparks MA; Buckley AF; Spurney RF
Biochem Biophys Res Commun; 2014 Feb; 444(4):622-7. PubMed ID: 24491571
[TBL] [Abstract][Full Text] [Related]
2. Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease.
Wang L; Sha Y; Bai J; Eisner W; Sparks MA; Buckley AF; Spurney RF
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F430-F439. PubMed ID: 28490532
[TBL] [Abstract][Full Text] [Related]
3. Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion.
Chang JH; Paik SY; Mao L; Eisner W; Flannery PJ; Wang L; Tang Y; Mattocks N; Hadjadj S; Goujon JM; Ruiz P; Gurley SB; Spurney RF
PLoS One; 2012; 7(4):e33942. PubMed ID: 22496773
[TBL] [Abstract][Full Text] [Related]
4. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
5. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
6. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
Hong Q; Zhang L; Das B; Li Z; Liu B; Cai G; Chen X; Chuang PY; He JC; Lee K
Kidney Int; 2018 Jun; 93(6):1330-1343. PubMed ID: 29477240
[TBL] [Abstract][Full Text] [Related]
7. A novel mouse model of podocyte depletion.
Wang L; Tang Y; Howell DN; Ruiz P; Spurney RF
Nephron Exp Nephrol; 2012; 121(1-2):e10-22. PubMed ID: 23095233
[TBL] [Abstract][Full Text] [Related]
8. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury.
Zhang L; Zhang Q; Liu S; Chen Y; Li R; Lin T; Yu C; Zhang H; Huang Z; Zhao X; Tan X; Li Z; Ye Z; Ma J; Zhang B; Wang W; Shi W; Liang X
Kidney Int; 2017 Jul; 92(1):140-153. PubMed ID: 28318634
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ
Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330
[TBL] [Abstract][Full Text] [Related]
10. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
11. Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice.
Wang L; Chang JH; Buckley AF; Spurney RF
Kidney Int; 2019 Feb; 95(2):321-332. PubMed ID: 30665571
[TBL] [Abstract][Full Text] [Related]
12. Hyperoside reduces albuminuria in diabetic nephropathy at the early stage through ameliorating renal damage and podocyte injury.
Zhang J; Fu H; Xu Y; Niu Y; An X
J Nat Med; 2016 Oct; 70(4):740-8. PubMed ID: 27255369
[TBL] [Abstract][Full Text] [Related]
13. Podocyte-specific knockin of PTEN protects kidney from hyperglycemia.
Wang H; Feng Z; Xie J; Wen F; Jv M; Liang T; Li J; Wang Y; Zuo Y; Li S; Li R; Li Z; Zhang B; Liang X; Liu S; Shi W; Wang W
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1096-F1107. PubMed ID: 29361670
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy.
Lin J; Shi Y; Peng H; Shen X; Thomas S; Wang Y; Truong LD; Dryer SE; Hu Z; Xu J
J Pathol; 2015 May; 236(1):30-40. PubMed ID: 25641678
[TBL] [Abstract][Full Text] [Related]
15. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
Theranostics; 2021; 11(10):4728-4742. PubMed ID: 33754024
[No Abstract] [Full Text] [Related]
16. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
Jung E; Kim J; Ho Kim S; Kim S; Cho MH
Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
[TBL] [Abstract][Full Text] [Related]
17. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
18. Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.
Guo C; Liu Y; Zhao W; Wei S; Zhang X; Wang W; Zeng X
J Cell Mol Med; 2015 Sep; 19(9):2273-85. PubMed ID: 26103809
[TBL] [Abstract][Full Text] [Related]
19. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.
Zhang H; Nair V; Saha J; Atkins KB; Hodgin JB; Saunders TL; Myers MG; Werner T; Kretzler M; Brosius FC
Kidney Int; 2017 Oct; 92(4):909-921. PubMed ID: 28554737
[TBL] [Abstract][Full Text] [Related]
20. An adjustment in BMP4 function represents a treatment for diabetic nephropathy and podocyte injury.
Fujita Y; Tominaga T; Abe H; Kangawa Y; Fukushima N; Ueda O; Jishage KI; Kishi S; Murakami T; Saga Y; Kanwar YS; Nagai K; Doi T
Sci Rep; 2018 Aug; 8(1):13011. PubMed ID: 30158674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
